RespirAI Medical

Name

RespirAI Medical

Legal name

RespirAI Ltd.

Website

https://respirai.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Remote Patient Monitoring

SIC

Services-Home Health Care Services (8082)

akta.pro primary industry

Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking) (HLAHACAI)

akta.pro secondary industries

Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD), Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB), Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI), Elderly/Frail & Assisted Living Connected Care (PERS/Fall Detection) (HLACAFAE)

Keywords

• Remote patient monitoring
• AI respiratory platform
• Wearable health monitoring
• COPD disease management
• Chronic disease detection

Headquarters

HQ city

Herzliya

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare Monitoring Platform: Pre-revenue startup in clinical trial phase. Revenue model not yet disclosed publicly.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

RespirAI Medical develops an AI-powered wearable home monitoring platform that passively captures medical physiological data and analyzes deviations from patient clinical baselines to enable early detection of chronic respiratory disease exacerbations, primarily COPD. The smartwatch-based system uploads data to the cloud where advanced AI algorithms automatically generate alerts shared with patients, caregivers, and care teams.

Product overview

RespirAI Medical offers a unified AI-powered home monitoring platform for managing chronic respiratory diseases. The platform consists of a wearable device (smartwatch-based system) that passively captures medical physiological data, combined with cloud-based AI algorithms that analyze deviations from patient clinical baselines to detect early signs of disease exacerbations. Data analysis results are shared with patients, caregivers, and care teams when notifications are triggered. The initial target condition is COPD, with expansion to other chronic respiratory diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• RespirAI Home Monitoring Platform An AI-powered home monitoring platform consisting of a wearable smartwatch-based system that passively captures medical physiological data, combined with cloud-based AI algorithms that analyze deviations from patient clinical baselines to detect early signs of respiratory disease exacerbations. Designed for patients with chronic respiratory diseases (initially COPD), their caregivers, and healthcare providers.

Quantifiable outcome

• Early detection of health deterioration before patient reports symptoms or experiences physiological decline
• +1 more outcomes

Named customers3 records

Segments3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered major, supporting, core and foundational.

• UNeMed CorporationmajorStrategic or Co-development Partner · 24 June 2025Early support and continued partnership. Technology originated from academic research at University of Nebraska at Omaha. UNeMed provides ongoing backing and support for the startup.
• UNeTech InstitutemajorStrategic or Co-development Partner · 24 June 2025Continued backing and support for RespirAI. Partnership supported by grant funding and ecosystem development.
• American Thoracic SocietysupportingOthers · 20 May 2025Presented poster at Respiratory Innovation Summit during ATS 2025 Conference. Engages with forward-thinking community of innovators, clinicians, investors, and industry leaders.
• Right at HomecoreStrategic or Co-development Partner · 2 February 2025Strategic collaboration to co-develop and commercialize AI-powered home monitoring platform for COPD management. Partnership supported by BIRD Foundation grant. Combines RespirAI's AI technology with Right at Home's extensive home care experience to detect early signs of health deterioration, reduce hospitalizations, and improve quality of life for patients.
• Bio NebraskasupportingOthers · 3 November 2024RespirAI Medical joined Bio Nebraska, a statewide association dedicated to supporting the growth of Nebraska's bioscience sector. Partnership strengthens ties to the region and reflects commitment to collaboration and innovation in the life sciences ecosystem.
• Mayo CliniccoreStrategic or Co-development Partner · 1 November 2023Know-how agreement for development of AI respiratory platform. Collaboration expanded in 2025 to support investigator-initiated clinical trial evaluating AI-powered wearable platform for remote monitoring of COPD patients. Study aims to assess technology's ability to detect early signs of exacerbations and pneumothorax.
• Soroka Medical CentersupportingStrategic or Co-development Partner · 4 September 2023Initial clinical study site where RespirAI recruited first patient, officially launching clinical study to assess effectiveness of the platform on prediction of COPD exacerbations.
• University of Nebraska at OmahafoundationalStrategic or Co-development PartnerCore technology based on invention of researchers from the University of Nebraska at Omaha. Academic research evolved into development of AI-powered home monitoring platform.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• ResMed: Global leader in sleep and respiratory care devices, including connected CPAP and ventilation platforms for chronic respiratory disease management. Comparable to RespirAI because both target chronic respiratory patients with connected monitoring, though ResMed operates at vastly larger scale and across a broader sleep-respiratory portfolio.
• Philips Respironics: Broad respiratory and sleep care franchise within Philips, including connected CPAP, ventilation and respiratory care platforms. Comparable to RespirAI on disease area and connected-care ambition, but operates as a large incumbent across the full respiratory care continuum.

Direct peers

• Propeller Health (ResMed): Digital respiratory health platform (now part of ResMed) using sensors and AI to monitor inhaler use and predict exacerbations in asthma and COPD. One of the closest direct competitors to RespirAI because both pursue AI-driven early detection of respiratory deterioration via connected, passive-style monitoring.
• Spire Health: Wearable respiratory monitoring startup whose product tracks breathing patterns continuously to detect changes tied to chronic respiratory conditions. Closely comparable to RespirAI as a small, wearable-first respiratory RPM company pursuing disease-management use cases via passive sensing.
• Adherium: Digital respiratory monitoring company focused on inhaler adherence and remote patient monitoring for asthma and COPD. Comparable to RespirAI as a respiratory RPM/digital health peer targeting the same patient population and use case of early intervention.

Emerging players

• Teva Pharmaceutical (Digihaler): Pharmaceutical company with Digihaler connected inhaler platform collecting respiratory data from patients with asthma and COPD. Comparable to RespirAI on respiratory digital health monitoring and exacerbation-relevant data capture for chronic lung disease patients.
• Hexoskin: Wearable health monitoring platform capturing cardiopulmonary and activity data via smart shirts for clinical and research use. Comparable to RespirAI on wearable physiologic sensing and AI-driven monitoring of chronic conditions, particularly respiratory and cardiopulmonary.
• BioIntellisense: Remote patient monitoring company offering continuous wearable vital-sign monitoring (Biosticker) plus AI analytics for clinical decision support. Comparable to RespirAI on the RPM-plus-AI business model for chronic disease management, though BioIntellisense focuses on multi-parameter vitals rather than respiratory-specific coupling.

Others

• Vivify Health: Connected health / RPM platform enabling chronic care management at home, including respiratory and other chronic disease pathways. Comparable to RespirAI on home-based RPM and chronic condition management delivery model, though Vivify's offering is more platform-and-kit than proprietary wearable.
• Life365: RPM and chronic care management provider that integrates wearable sensors and connected devices for home-based monitoring of conditions including COPD and CHF. Comparable to RespirAI on the broader home-RPM, chronic-disease-management category it serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/respirai-medical

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RespirAI Medical